aztreonam

(redirected from Cayston)
Also found in: Dictionary, Medical.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for aztreonam

an antibiotic (trade name Azactam) used against severe infections

References in periodicals archive ?
Cayston is supplied in a form that must be reconstituted.
The approval comes as no surprise, as the orphan drug was seen as an urgently needed therapeutic to treat the respiratory and pulmonary symptoms of CE and led the FDA's Anti-Infective Drugs Advisory Committee to overwhelmingly support approval of Cayston (aztreonam for inhalation solution).
The orphan drug was seen as an urgently needed agent to treat the respiratory and pulmonary symptoms of CF, which led the FDA's Anti-Infective Drugs Advisory Committee to overwhelmingly support approval of Cayston (aztre-onam for inhalation solution).
The foundation is also working with Gilead's marketing team to establish the Cayston Access Program, a call center developed with the Cystic Fibrosis Foundation Pharmacy (a wholly owned subsidiary of the Cystic Fibrosis Foundation), which will assist people with cystic fibrosis and members of their care team with insurance verification, referral to participating specialty pharmacies, claims support, and copay assistance.
The increase in sales of other products was due primarily to sales volume growth of AmBisome in Europe and Latin America and Cayston in the United States.
Contract award: supply of medication cayston * nebul 75 mg 84fl +88 f + ne.
In March 2010, the FDA approved Gilead Sciences' Cayston to treat Pseudomonas aeruginosa infections in CF patients.
The unique liposomal formulation improves the pharmacokinetic profile to once daily, versus twice daily and three times a day for TOBI (tobramycin) and Cayston (aztreonam), respectively.
In October, Gilead announced positive data from its head-to-head Phase III clinical trial of Cayston versus tobramycin inhalation solution in cystic fibrosis patients with P.
Moreover, the FDA approval of Cayston earlier this year is also a positive.
aeruginosa) achieved its co-primary endpoint of superiority of Cayston for mean actual change in forced expiratory volume in one second (FEV1, a measure of lung function) percent predicted across three treatment cycles (six months).
In June, Gilead announced that its head-to-head Phase III clinical trial of Cayston versus tobramycin inhalation solution in cystic fibrosis patients with P.
In February, Gilead announced that the FDA granted marketing approval for Cayston as a treatment for the improvement of respiratory symptoms in cystic fibrosis patients with P.
Cayston is administered at a dose of 75 mg three times daily over a 28-day period and is delivered via the Altera([R]) Nebulizer System, a portable, drug-specific delivery device using the eFlow([R])Technology Platform, developed by PARI Pharma GmbH.